Our findings support the clinical development of triple combinations with fulvestrant, CDK4/6i, and AKTi in pre-treated ER+ advanced breast cancer, particularly in tumors exhibiting high levels of p-AKT, to improve patient survival. Here, AKT1 is linked to breast cancer.